Mesoblast Long Term Debt

The latest long-term debt for MESO is $66M as of December 2025. That compares with $110M in the prior-year period — down 37.8% year over year. Investors often review this figure alongside Mesoblast's historical trend and sector peers before judging valuation or financial health.

Over the past year, MESO's long-term debt moved from $110M to $66M — a 37.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Mesoblast's operating scale or balance-sheet position.

A long-term debt figure of $66M for MESO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting MESO's long-term debt ($66M), review year-over-year change from $110M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Mesoblast's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.